drugset / Trial / NCT05604898
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2023-05
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 608 | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | 608 | Monoclonal antibody | 80 mg | Subcutaneous |
| Subject | 608 | Monoclonal antibody | 160 mg | Subcutaneous |